# Eikon Therapeutics, Inc.: filings

EIKN · Nasdaq · CIK 1861123 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eikn.md) · [Financials](/companies/eikn/financials.md) · [Filings](/companies/eikn/filings.md) · [Insiders](/companies/eikn/insiders.md)

## Reports and events: 15 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (3 14, 4 14, 8-K 9, SCHEDULE 13G 6, D 4, DRS/A 3, SCHEDULE 13G/A 3, 10-Q 2, 10-K 1, 424B4 1, 8-A12B 1, CERT 1, DRS 1, EFFECT 1, S-1 1, S-1/A 1, S-1MEF 1, S-8 1, SCHEDULE 13D 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 09:15 ET | [8-K](/filings/0001193125-26-429549.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429549 |
| 2026-08-14 | 20:44 ET | [8-K](/filings/0001193125-26-349936.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-349936 |
| 2026-08-13 | 16:10 ET | [10-Q](/filings/0001193125-26-349185.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349185 |
| 2026-08-13 | 16:06 ET | [8-K](/filings/0001193125-26-349154.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349154 |
| 2026-08-03 | 16:39 ET | [8-K](/filings/0001193125-26-330710.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-330710 |
| 2026-06-10 | 16:15 ET | [8-K](/filings/0001193125-26-265861.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-265861 |
| 2026-06-01 | 07:30 ET | [8-K](/filings/0001193125-26-249725.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-249725 |
| 2026-05-11 | 16:13 ET | [10-Q](/filings/0001193125-26-216791.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216791 |
| 2026-05-11 | 16:05 ET | [8-K](/filings/0001193125-26-216744.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-216744 |
| 2026-03-30 | 08:02 ET | [8-K](/filings/0001193125-26-130449.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-130449 |
| 2026-03-30 | 07:09 ET | [10-K](/filings/0001193125-26-130395.md) | Annual report, period 2025-12-31 | 0001193125-26-130395 |
| 2026-02-12 | 18:48 ET | [SCHEDULE 13D](/filings/0001193125-26-049209.md) | Ownership report, active investor | 0001193125-26-049209 |
| 2026-02-06 | 16:14 ET | [8-K](/filings/0001193125-26-041201.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-041201 |
| 2026-01-28 | 06:03 ET | [S-1/A](/filings/0001193125-26-025565.md) | Registration statement, amended | 0001193125-26-025565 |
| 2026-01-09 | 16:02 ET | [S-1](/filings/0001193125-26-008888.md) | Registration statement | 0001193125-26-008888 |

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 06:02 ET. No prices; not investment advice.